# CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia

> **NCT03882203** · PHASE2 · COMPLETED · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 18 (actual)

## Conditions studied

- Refractory Hematologic Cancer
- Allogeneic Stem Cell Transplantation

## Interventions

- **DRUG:** CLAGE-FluBu

## Key facts

- **NCT ID:** NCT03882203
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-01
- **Primary completion:** 2021-08-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03882203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03882203, "CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03882203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*